A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

City of Hope National Medical Center /ID# 270526, Duarte, California, United States

City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120, Irvine, California, United States

USC Norris Comprehensive Cancer Center /ID# 271573, Los Angeles, California, United States

UC Irvine Medical Center /ID# 270507, Orange, California, United States

UCLA - Santa Monica /ID# 275995, Santa Monica, California, United States

University of Chicago Medical Center /ID# 270517, Chicago, Illinois, United States

Washington University /ID# 275757, St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center /ID# 271228, New York, New York, United States

Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269, Philadelphia, Pennsylvania, United States

SCRI Oncology Partners /ID# 272750, Nashville, Tennessee, United States

Nanfang Hospital - Southern Medical University /ID# 276916, Guangzhou, Guangdong, China

Zhongshan Hospital Fudan University /ID# 276917, Shanghai, Shanghai Municipality, China

Rambam Health Care Campus /ID# 270604, Haifa, Israel

Hadassah Medical Center-Hebrew University /ID# 271235, Jerusalem, Israel

Rabin Medical Center. /ID# 271236, Petah Tikva, Israel

National Cancer Center Hospital East /ID# 270585, Kashiwa-shi, Chiba, Japan

Kansai Medical University Hospital /ID# 272884, Hirakata-shi, Osaka, Japan

National Cancer Center Hospital /ID# 270583, Chuo-Ku, Tokyo, Japan

Fdi Clinical Research /ID# 272960, San Juan, Puerto Rico

Hospital Universitario Fundacion Jimenez Diaz /ID# 272718, Madrid, Spain

Hospital Universitario HM Sanchinarro /ID# 272719, Madrid, Spain

National Taiwan University Hospital /ID# 270593, Taipei, Taiwan